Clinical Trial Update: Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is recruiting to evaluate Nituzumab plus Serplulimab in combination with SBRT for cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Nituzumab (nituzumab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Cervical Cancer | Phase 2 | Status: RECRUITING